<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815736</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-292-0109</org_study_id>
    <secondary_id>2012-005114-20</secondary_id>
    <nct_id>NCT01815736</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants</brief_title>
  <official_title>A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the non-inferiority of switching to a&#xD;
      tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining&#xD;
      tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically&#xD;
      suppressed HIV-infected participants as determined by having HIV-1 RNA &lt; 50 copies/mL at Week&#xD;
      48.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2013</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 16, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
    <description>Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine BMD at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
    <description>Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
    <description>The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.&#xD;
EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants achieving HIV-1 RNA &lt; 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>The percentage of participants achieving HIV-1 RNA &lt; 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
    <description>The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count at Weeks 96</measure>
    <time_frame>Baseline; Week 96</time_frame>
    <description>The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1443</enrollment>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>E/C/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks.&#xD;
Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stay on Baseline Treatment Regimen (SBR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks.&#xD;
Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E/C/F/TAF</intervention_name>
    <description>150/150/200/10 mg FDC tablet administered orally once daily</description>
    <arm_group_label>E/C/F/TAF</arm_group_label>
    <other_name>EVG/COBI/FTC/TAF; Genvoya®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E/C/F/TDF</intervention_name>
    <description>150/150/200/300 mg FDC tablet administered orally once daily</description>
    <arm_group_label>Stay on Baseline Treatment Regimen (SBR)</arm_group_label>
    <other_name>Stribild®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFV/FTC/TDF</intervention_name>
    <description>600/200/300 mg FDC tablet administered orally once daily</description>
    <arm_group_label>Stay on Baseline Treatment Regimen (SBR)</arm_group_label>
    <other_name>Atripla®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>100 mg tablet administered orally once daily</description>
    <arm_group_label>Stay on Baseline Treatment Regimen (SBR)</arm_group_label>
    <other_name>Norvir®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV</intervention_name>
    <description>300 mg capsule administered orally once daily</description>
    <arm_group_label>Stay on Baseline Treatment Regimen (SBR)</arm_group_label>
    <other_name>Reyataz®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF</intervention_name>
    <description>200/300 mg tablet administered orally once daily</description>
    <arm_group_label>Stay on Baseline Treatment Regimen (SBR)</arm_group_label>
    <other_name>Truvada®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COBI</intervention_name>
    <description>150 mg tablet administered orally once daily</description>
    <arm_group_label>Stay on Baseline Treatment Regimen (SBR)</arm_group_label>
    <other_name>Tybost®</other_name>
    <other_name>GS-9350</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and sign a written informed consent form, which must be obtained&#xD;
             prior to initiation of study procedures&#xD;
&#xD;
          -  Currently receiving antiretroviral therapy consisting of E/C/F/TDF, EFV/FTC/TDF,&#xD;
             RTV+ATV+FTC/TDF, or COBI+ATV+FTC/TDF for ≥ 6 consecutive months preceding the final&#xD;
             visit in their earlier study&#xD;
&#xD;
          -  Completion of the Week 144 visit in studies GS-US-236-0102, GS-US-236-0103,&#xD;
             GS-US-216-0114, or completion of the Week 96 visit in study GS-US-264-0110 (only&#xD;
             participants on an EFV-based regimen), or completion of studies GS-US-236-0104,&#xD;
             GS-US-216-0105&#xD;
&#xD;
          -  Plasma human immunodeficiency virus type 1-ribonucleic acid (HIV-1 RNA) concentrations&#xD;
             at undetectable levels for at least 6 consecutive months prior to the screening visit&#xD;
             and have HIV RNA &lt; 50 copies/mL at the screening visit&#xD;
&#xD;
          -  Normal echocardiograph (ECG)&#xD;
&#xD;
          -  Estimated glomerular filtration rate (GFR) ≥ 50 mL/min according to the&#xD;
             Cockcroft-Gault formula for creatinine clearance&#xD;
&#xD;
          -  Hepatic transaminases (aspartate aminotransferase [AST] and alanine aminotransferase&#xD;
             [ALT]) ≤ 5 × upper limit of the normal range (ULN)&#xD;
&#xD;
          -  Direct bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
          -  Serum amylase ≤ 5 × ULN&#xD;
&#xD;
          -  Females of childbearing potential must agree to utilize highly effective contraception&#xD;
             methods or be non-heterosexually active or practice sexual abstinence from screening&#xD;
             throughout the duration of study treatment and for 12 weeks following the last dose of&#xD;
             study drug if receiving EFV/FTC/TDF regimen, and 30 days for those assigned to all&#xD;
             other regimens.&#xD;
&#xD;
          -  Female participants who utilize hormonal contraceptive as one of their birth control&#xD;
             methods must have used the same method for at least three months prior to study dosing&#xD;
&#xD;
          -  Female participants who have stopped menstruating for ≥ 12 months but do not have&#xD;
             documentation of ovarian hormonal failure must have a serum follicle stimulating&#xD;
             hormone (FSH) level at screening within the post-menopausal range based on the Central&#xD;
             Laboratory reference range&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within&#xD;
             the 30 days prior to screening&#xD;
&#xD;
          -  Hepatitis B surface antigen position&#xD;
&#xD;
          -  Hepatitis C antibody positive&#xD;
&#xD;
          -  Participants experiencing decompensated cirrhosis&#xD;
&#xD;
          -  Females who are breastfeeding&#xD;
&#xD;
          -  Positive serum pregnancy test&#xD;
&#xD;
          -  Have an implanted defibrillator or pacemaker&#xD;
&#xD;
          -  Current alcohol or substance use judged by the Investigator to potentially interfere&#xD;
             with subject study compliance&#xD;
&#xD;
          -  History of malignancy within the past 5 years or ongoing malignancy other than&#xD;
             cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous&#xD;
             squamous carcinoma&#xD;
&#xD;
          -  Active, serious infections (other than HIV-1 infection) requiring parenteral&#xD;
             antibiotic or antifungal therapy within 30 days prior to baseline&#xD;
&#xD;
          -  Any other clinical condition or prior therapy that, in the opinion of the&#xD;
             Investigator, would make the subject unsuitable for the study or unable to comply with&#xD;
             dosing requirements&#xD;
&#xD;
          -  Participation in any other clinical trial without prior approval from the sponsor is&#xD;
             prohibited while participating in this trial&#xD;
&#xD;
          -  Participants receiving ongoing therapy with drugs not to be used with elvitegravir&#xD;
             (EVG), COBI, FTC, TDF, ATV, RTV, EFV, and TAF or participants with any known allergies&#xD;
             to the excipients of E/C/F/TDF, E/C/F/TAF, EFV/FTC/TDF, ATV, COBI, RTV, or FTC/TDF&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Center for HIV/AIDS</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical Group</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health for Life Clinic PLLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHF Research Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Keith Wensley, MD, Inc., A Medical Corporation</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Living Hope Clinical Foundation</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey Goodman Special Care Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter J Ruane, MD, Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthony Mills MD Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Coast Medical Group</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alameda County Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay AIDS Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Playa Medical Group and Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolis Medical Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center, Clinical Trials Unit</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Hospital</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Research LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenwich Hospital</name>
      <address>
        <city>Greenwich</city>
        <state>Connecticut</state>
        <zip>06830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University HIV Clinical Trials Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physicians Group</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitman Walker Clinic</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Medical Associates, PC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therafirst Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Health/Comprehensive Care Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gary J. Richmond,M.D.,P.A.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wohlfeiler, Piperato and Associates, LLC</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Kinder Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDOCF/ Value Health MD, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida HIV Clinical Research Unit / Hillsborough County Health Department</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Research Institute Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Comprehensive Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta ID Group, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Specialists of Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercer University School of Medicine</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hawaii - Hawaii Center for AIDS</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruth M. Rothstein CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthStar Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of New England</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Infectious Diseases Clinical Research</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central West Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton Healthcare</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Care</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michaels Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Jersey Infectious Disease</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SouthWest CARE Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate ID Association</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - AIDS Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Hospital Queens</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital, Divison of Infectious Diseases</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greiger Clinic</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center- Division of Infectious Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea Village Medical, PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ricky K. Hsu, MD</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of NC AIDS Clinical Trials Unit</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center-Myers Park</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosedale Infectious Diseases</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Arms, Inc./ Peabody Health Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Infectious Disease Clinical Research, Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant County Infectious Disease Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Garcia's Family Health Group</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon E. Crofoot MD PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Access Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCOL Center for Clinical Research</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Alliance for Research &amp; Education, Infectious Diseases (CARE-ID)</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Shalit, M.D.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Sydney Doctors</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical practice</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital, Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albion Street Centre</name>
      <address>
        <city>Surry Hills</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Sexual Health Clinic</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Clinic</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3068</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prahran Market Clinic</name>
      <address>
        <city>South Yarra</city>
        <state>Victoria</state>
        <zip>3141</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMZ Baumgartner Hoehe - Otto-Wagner-Spital</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Erasme - ULB</name>
      <address>
        <city>Ghent</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De Pesquisa Clinica Evandro Chagas - Fundação Oswaldo Cruz</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>São Paulo Secretaria da Saúde - Instituto De Infectologia Emilio Ribas</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>São Paulo Secretaria da Saúde - Centro de Referência e Treinamento em DST/AIDS</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04121-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ubc Downtown I.D. Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Regional Health Authority - Health Sciences Centre Winnipeg</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maple Leaf Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique medicale l'Actuel</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale du Quartier Latin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique OPUS</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC) - Montral Chest Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epidemiklinikken 5112, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dominicano de Estudios Virologicos - IDEV</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Archet 1 CHU de Nice - 6ème Niveau</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EPIMED GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for HIV and Hepatogastroenterology</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infektio Research GmbH / Infektiologikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60311</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICH Study Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne, Department of Internal Medicine</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUC Research GmbH</name>
      <address>
        <city>München</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Luigi Sacco 1° Divisione Malattie Infettive</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Centro San Raffaele del Monte Tabor</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Malattie Infettive &quot;Lazzaro Spallanzani&quot; IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprensorio Amedeo Di Savoia Birago Di Vische</name>
      <address>
        <city>Torino</city>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antiguo Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</name>
      <address>
        <city>Guadalajara</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis, Afdeling Infectieziekten</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servico De Doencas Infecciosas - Hospital De Sao Joao</name>
      <address>
        <city>Porto</city>
        <zip>4202-451</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Clinical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Caribbean Healthcare System</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari De Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Infektiologie, Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross AIDS Research Center and Faculty of Medicine Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj HospitalDepartment of Preventive and Social Medicine, Faculty of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai University, Faculty of Medicine, Department of Medicine</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and the London NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Courtyard Clinic, St. Georges Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Dominican Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S; GS-US-292-0109 team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016 Jan;16(1):43-52. doi: 10.1016/S1473-3099(15)00348-5. Epub 2015 Nov 2.</citation>
    <PMID>26538525</PMID>
  </results_reference>
  <results_reference>
    <citation>Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2.</citation>
    <PMID>28259777</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown T, Yin MT, Gupta S, Katlama C, et al. Switching from TDF to TAF in HIV-infected adults with low BMD: a pooled analysis. 24th Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2017; poster presentation: abstract #683.</citation>
  </results_reference>
  <results_reference>
    <citation>Podzamczer D, Viciana P, Rijnders B, Shalit P, et al. Switching from Tenofovir disoproxil fumarate to tenofovir alafenamide in patients with high risk for chronic kidney disease. 8th National Congress of the AIDS Study Group (GESIDA) and Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) held jointly with the 9th Teacher Meeting of AIDS Research Network 2016; poster presentation: abstract #P-188.</citation>
  </results_reference>
  <results_reference>
    <citation>Orkin C, Rjinders B, Stephan C, McKellar M, et al. Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): Week 48 data in virologically suppressed adults. Annual Conference of the British Association for Sexual Health and HIV (BASHH) 2016; poster presentation: abstract # P045.</citation>
  </results_reference>
  <results_reference>
    <citation>Mills A, Andrade J, Koenig E, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 13th Congress for Infectious Diseases and Tropical Medicine (KIT) 2016; poster presentation: abstract #eP-038.</citation>
  </results_reference>
  <results_reference>
    <citation>Overton ET, Shalit P, Crofoot G, Benson P, et al. Switch from TDF regimens to E/C/F/TAF is associated with improved bone mineral density (BMD), decreased serum PTH and decreased bone turnover biomarkers. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; poster presentation: abstract #PW-027.</citation>
  </results_reference>
  <results_reference>
    <citation>Huhn G, Rijnders B, Thompson M, Tebas P, et al. Switching from TDF to TAF in patients with high risk for CKD. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; oral presentation: https://www.natap.org/2016/HIV/062116_01.htm.</citation>
  </results_reference>
  <results_reference>
    <citation>Abram M, Margot NA, Cox S, Ram RR, et al. Pooled week-48 analysis of HIV-1 drug resistance in E/C/F/TAF (Genvoya) phase 3 studies. 23rd Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2016, poster presentation: abstract #496.</citation>
  </results_reference>
  <results_reference>
    <citation>Abram M, Margot NA, Cox S, Ram RR, et al. Pooled week-48 analysis of HIV-1 drug resistance in E/C/F/TAF (Genvoya) phase 3 studies. 25th International HIV Drug Resistance Workshop - Informed Horizons, LLC 2016; poster presentation: abstract #33.</citation>
  </results_reference>
  <results_reference>
    <citation>Mills A, Andrade J, Di Perri G, Van Lunzen J, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 8th Biennial Conference on HIV Pathogenesis and Treatment and Prevention of the International AIDS Society (IAS) 2015; oral presentation: abstract #TUAB0102.</citation>
  </results_reference>
  <results_reference>
    <citation>Shamblaw D, Van Lunzen J, Orkin C, Bloch M, eta al. Switching from Atripla (ATR) to a tenofovir alafenamide (TAF)-based single tablet regimen: week 48 data in virologically suppressed adults. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2015; oral presentation; https://natap.org/2015/ICAAC/ICAAC_13.htm.</citation>
  </results_reference>
  <results_reference>
    <citation>Thompson M, Morales-Ramirez J, Mcdonald C, Rachlis A, et al. Switching from a tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF)-based single tablet regimen (STR): Week 48 data in HIV-1 infected virologically suppressed adults. Spring Conference of the Society for Healthcare Epidemiology of America (SHEA) 2015; oral presentation: abstract #725.</citation>
  </results_reference>
  <results_reference>
    <citation>Rijnders B, Stephan C, Lazzarin A, Squires K, et al. Switching from ritonavir or cobicistat boosted atazanavir (ATV) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF)-based single tablet regimen (STR): week 48 data in virologically suppressed adults. 15th European AIDS Conference (EACS) and 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV 2015; poster presentation: abstract #577.</citation>
  </results_reference>
  <results_reference>
    <citation>Lutz T, Benson P, Goffard J-C, Haubrich R, et al. Patient reported outcomes (PRO) over 48 weeks in a randomized, open-label trial of patients with HIV switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF). 15th European AIDS Conference (EACS) and 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV 2015; poster presentation: abstract #324.</citation>
  </results_reference>
  <results_reference>
    <citation>Viciana P, Mills A, Andrade J, Diperri G, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 7th National Congress of the AIDS Study Group (GESIDA) and Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) held jointly with the 8th Teacher Meeting of AIDS Research Network 2015; oral presentation: abstract #PO-08.</citation>
  </results_reference>
  <results_reference>
    <citation>Mills A, Andrade-Villanueva J, DiPerri G, Van Luzen J, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: Data in virologically suppressed adults through 48 weeks of treatment. 8th Annual International AIDS Society meeting 2015; oral presentation: abstract #839.</citation>
  </results_reference>
  <results_reference>
    <citation>Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide vs tenofovir DF in women: pooled analysis of 7 clinical trials. Annual Meeting of the American Pharmacists Association (APhA) - Virtual 2020; poster presentation: abstract #209.</citation>
  </results_reference>
  <results_reference>
    <citation>Stellbrink H, Gandhi-Patel B, Zhong L, Das M, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. Annual Meeting of the American Pharmacists Association (APhA) - Virtual 2020; poster presentation: abstract #205.</citation>
  </results_reference>
  <results_reference>
    <citation>Stellbrink H-J, Post FA, Podzamczer D, Arribas J, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. 15th Congress on Infectious Diseases and Tropical Medicine - German Society for Infectious Diseases (DPID) held jointly with the 29th Annual Meeting of the German Society for Pediatric Infectiology (DGPI) 2020; poster presentation: abstract #A-343.</citation>
  </results_reference>
  <results_reference>
    <citation>Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.</citation>
    <PMID>30932951</PMID>
  </results_reference>
  <results_reference>
    <citation>Hermansson L, Yilmaz A, Price RW, Nilsson S, McCallister S, Makadzange T, Das M, Zetterberg H, Blennow K, Gisslen M. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS One. 2019 Dec 11;14(12):e0226276. doi: 10.1371/journal.pone.0226276. eCollection 2019.</citation>
    <PMID>31826005</PMID>
  </results_reference>
  <results_reference>
    <citation>Stellbrink H-J, Post FA, Podzamczer D, Arribas J, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. 17th European AIDS Conference of the European AIDS Clinical Society (EACS) 2019; poster presentation: abstract #PE9-50.</citation>
  </results_reference>
  <results_reference>
    <citation>Pepperrell T, Hughes S, Gotham D, Pozniak A, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety? 17th European AIDS Conference of the European AIDS Clinical Society (EACS) 2019; poster presentation: abstract #PE3-8.</citation>
  </results_reference>
  <results_reference>
    <citation>Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide vs. tenofovir DF in women: pooled analysis of 7 clinical trials. 9th Edition International Workshop on HIV and Women - Virology Education 2019; poster presentation: abstract #21.</citation>
  </results_reference>
  <results_reference>
    <citation>Dejesus E, Federico Andrade Villanueva J, Ramon Arribas Lopez J, Brinson C, et al. Tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in hispanic/latinx and black participants: efficacy, bone and renal safety results from a pooled analysis of 7 clinical trials. IDWeek Meeting of the Infectious Diseases Society of America (IDSA) 2019; poster presentation: abstract #318.</citation>
  </results_reference>
  <results_reference>
    <citation>Walmsley S, Andany N, Brar I, Brinson C, et al. Tenofovir alafenamide VS tenofovir DF in women: pooled analysis of 7 clinical trials. 28th Annual Canadian Conference on HIV/AIDS Research - Canadian Association for HIV Research (CAHR) 2019; poster presentation: abstract #CSP9.04.</citation>
  </results_reference>
  <results_reference>
    <citation>Kim YS, Oka S, Chetchotisakd P, Clarke A, Supparatpinyo K, Avihingsanon A, Ratanasuwan W, Kiertiburanakul S, Ruxrungtham K, Yang S, Guo S, Liu Y, Das M, Tran D, McColl D, Corales R, Nguyen C, Piontkowsky D. Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. HIV Res Clin Pract. 2019 Jul 8:1-9. doi: 10.1080/15284336.2019.1589232. [Epub ahead of print]</citation>
    <PMID>31303140</PMID>
  </results_reference>
  <results_reference>
    <citation>Hermansson L, Price RW, Yilmaz A, Nilsson S, et al. Effect on plasma NFL, a marker or neuronal injury, after switching from TDF to TAF. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2019; oral presentation: abstract #127.</citation>
  </results_reference>
  <results_reference>
    <citation>Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide VS tenofovir DF in women: pooled analysis of 7 clinical trials. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2019; poster presentation: abstract #519.</citation>
  </results_reference>
  <results_reference>
    <citation>Orkin C, Castelli F, Yazdanpanah Y, Rockstroh J, et al. Cardiovascular disease risk assessments and fasting lipid changes in virologically suppressed patients randomized to switch to tenofovir alafenamide versus continuing tenofovir disoproxil fumarate. 22nd International AIDS Conference - International AIDS Society 2018; poster presentation: abstract #TUPEB104.</citation>
  </results_reference>
  <results_reference>
    <citation>Brown TT, Yin MT, Gupta SK, Short WR, et al. Combined effects of bisphosphonates &amp; TDF-&gt;TAF switch in HIV+ adults with low BMD. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2018; poster presentation: abstract #724.</citation>
  </results_reference>
  <results_reference>
    <citation>DeJesus E, Haas B, Segal-Maurer S, Ramgopal MN, Mills A, Margot N, Liu YP, Makadzange T, McCallister S. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Res Hum Retroviruses. 2018 Apr;34(4):337-342. doi: 10.1089/AID.2017.0203. Epub 2018 Mar 20.</citation>
    <PMID>29368537</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldstein D, Ward D, Brinson C, Crofoot G, et al. Week 96 efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in older, HIV-Infected virologically-suppressed adults. Annual Meeting of the American Geriatrics Society (AGS) 2017; poster presentation: abstract #A90.</citation>
  </results_reference>
  <results_reference>
    <citation>Ward D, Thompson M, Goldstein D, Brinson C, et al. Week 96 efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in older, HIV-infected treatment-naïve adults. Annual Meeting of the American Geriatrics Society (AGS) 2017; poster presentation: abstract #A91.</citation>
  </results_reference>
  <results_reference>
    <citation>Choe S, Podzamvzer D, Tashima K, McNicholl I, and McCallister S. Utilizing phase 3 clinical trial data to assess adverse event (AE) frequency of a potentially interacting medication (PIM) amlodipine with elvitegravir/cobicistat (EVG/COBI). Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP) 2017; poster presentation: abstract #7-068.</citation>
  </results_reference>
  <results_reference>
    <citation>Yin M, Gupta S, Nguyen-Cleary T, Mora M, and Das M. Switching from TDF to TAF in HIV-infected adults with low BMD: A pooled analysis. Congress on HIV and Hepatitis in the Americas - ViiV Healthcare UK Limited 2017; poster presentation: abstract #P021.</citation>
  </results_reference>
  <results_reference>
    <citation>Podzamczer D, Tashima K, Daar E, McGowan J, et al. Utilizing phase 3 clinical trial data to assess adverse event (AE) frequency of a potentially interacting medication (PIM) amlodipine with elvitegravir/cobicistat (EVG/COBI). International Congress of Drug Therapy in HIV Infection - International AIDS Society 2016; poster presentation: abstract #P314.</citation>
  </results_reference>
  <results_reference>
    <citation>Dejesus E, Haas B, Segal-Maurer S, Ramgopal M, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate (TDF) regimen to a tenofovir alafenamide (TAF) based regimen through 96 weeks (W96) of treatment. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; poster presentation: abstract # LB-087.</citation>
  </results_reference>
  <results_reference>
    <citation>Viciana P, Rijnders B, Shalit P, Liu Y et al. Cambio desde TDF a TAF en pacientes en alto riesgo de erc. 18th Congress of the Andalusian Society of Infectious Diseases (SAID) 2016; poster presentation: abstract #P-070.</citation>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <results_first_submitted>March 15, 2016</results_first_submitted>
  <results_first_submitted_qc>March 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 14, 2016</results_first_posted>
  <disposition_first_submitted>October 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>October 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 5, 2014</disposition_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV 1 Infected</keyword>
  <keyword>Virologically-Suppressed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>18 months after study completion</ipd_time_frame>
    <ipd_access_criteria>A secured external environment with username, password, and RSA code.</ipd_access_criteria>
    <ipd_url>https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in Dominican Republic, Puerto Rico, North America, South America, Europe, Australia, and Asia. The first participant was screened on 27 March 2013. The last study visit occurred on 01 April 2020.</recruitment_details>
      <pre_assignment_details>1559 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>E/C/F/TAF</title>
          <description>Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) fixed-dose combination (FDC) tablet administered once daily for up to 96 weeks.&#xD;
Extension Phase: After completing 96 weeks of randomized treatment, all participants were given the opportunity to receive open-label E/C/F/TAF until it became commercially available, or until Gilead elected to terminate the development of E/C/F/TAF.</description>
        </group>
        <group group_id="P2">
          <title>Stay on Baseline Treatment Regimen (SBR)</title>
          <description>Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks.&#xD;
Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants were given the opportunity to receive open-label E/C/F/TAF until it became commercially available, or until Gilead elected to terminate the development of E/C/F/TAF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Treatment Phase-Up to Week 96</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="963"/>
                <participants group_id="P2" count="480"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="914"/>
                <participants group_id="P2" count="445"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participants randomized and never treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Treatment Phase- After Week 96</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="905">9 participants who completed the Randomized Treatment Phase did not continue in the Extension E/C/F/TAF Treatment Phase.</participants>
                <participants group_id="P2" count="424">21 participants who completed the Randomized Treatment Phase did not continue in the Extension E/C/F/TAF Treatment Phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="854"/>
                <participants group_id="P2" count="398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set included participants who were randomized and received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>E/C/F/TAF</title>
          <description>Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)(150/150/200/10 mg) fixed-dose combination (FDC) tablet administered once daily for up to 96 weeks.&#xD;
Extension Phase: After completing 96 weeks of randomized treatment, all participants were given the opportunity to receive open-label E/C/F/TAF until it became commercially available, or until Gilead elected to terminate the development of E/C/F/TAF.</description>
        </group>
        <group group_id="B2">
          <title>Stay on Baseline Treatment Regimen (SBR)</title>
          <description>Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks.&#xD;
Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants were given the opportunity to receive open-label E/C/F/TAF until it became commercially available, or until Gilead elected to terminate the development of E/C/F/TAF.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="959"/>
            <count group_id="B2" value="477"/>
            <count group_id="B3" value="1436"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="10.1"/>
                    <measurement group_id="B2" value="41" spread="10.1"/>
                    <measurement group_id="B3" value="41" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="856"/>
                    <measurement group_id="B2" value="427"/>
                    <measurement group_id="B3" value="1283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="651"/>
                    <measurement group_id="B2" value="314"/>
                    <measurement group_id="B3" value="965"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Local regulators did not allow collection of race or ethnicity information</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="709"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="1101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Local regulators did not allow collection of race or ethnicity information</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="648"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominican Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA Category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 50 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="943"/>
                    <measurement group_id="B2" value="466"/>
                    <measurement group_id="B3" value="1409"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48</title>
        <description>The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set included participants who were randomized and received at least 1 dose of study drug.&#xD;
New Drug Application (NDA Data Cut) = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48</title>
          <description>The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Full Analysis Set included participants who were randomized and received at least 1 dose of study drug.&#xD;
New Drug Application (NDA Data Cut) = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NDA Data Cut</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="799"/>
                    <count group_id="O2" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6"/>
                    <measurement group_id="O2" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="959"/>
                    <count group_id="O2" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2"/>
                    <measurement group_id="O2" value="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NDA Data Cut</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the E/C/F/TAF group was at least 12% worse than the Stay on Baseline Regimen group; alternative hypothesis: the E/C/F/TAF group was less than 12% worse than the in Stay on Baseline Regimen group.</non_inferiority_desc>
            <p_value>0.051</p_value>
            <p_value_desc>The p-value for the superiority test used a 2-sided Cochran-Mantel-Haenszel (CMH) test, stratified by prior treatment regimen.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in percentages</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95.01</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
            <estimate_desc>The difference in percentages and its 95.01% confidence interval (CI) were calculated based on the Mantel-Haenszel (MH) proportion adjusted by the prior treatment regimen.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Participants</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the E/C/F/TAF group was at least 12% worse than the Stay on Baseline Regimen group; alternative hypothesis: the E/C/F/TAF group was less than 12% worse than the in Stay on Baseline Regimen group.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value for the superiority test used a 2-sided Cochran-Mantel-Haenszel (CMH) test, stratified by prior treatment regimen.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in percentages</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
            <estimate_desc>The difference in percentages and its 95% confidence interval (CI) were calculated based on the Mantel-Haenszel (MH) proportion adjusted by the prior treatment regimen.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48</title>
        <description>Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented.</description>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in the Hip DXA Analysis Set (participants who received ≥ 1 dose of study drug and had nonmissing baseline hip BMD) with available data were analyzed.&#xD;
NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48</title>
          <description>Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented.</description>
          <population>Participants in the Hip DXA Analysis Set (participants who received ≥ 1 dose of study drug and had nonmissing baseline hip BMD) with available data were analyzed.&#xD;
NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="902"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NDA Data Cut</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="733"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.949" spread="2.9956"/>
                    <measurement group_id="O2" value="-0.136" spread="2.9890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="869"/>
                    <count group_id="O2" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.468" spread="2.7136"/>
                    <measurement group_id="O2" value="-0.340" spread="2.8280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NDA Data Cut</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was from the analysis of variance (ANOVA) model including study treatment and prior treatment regimen as fixed effects.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Difference in least square means</param_type>
            <param_value>2.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.697</ci_lower_limit>
            <ci_upper_limit>2.459</ci_upper_limit>
            <estimate_desc>Difference in least squares means (LSM) and its 95% CI were from the ANOVA model including treatment and prior treatment regimen as fixed effects.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Participants</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was from the analysis of variance (ANOVA) model including study treatment and prior treatment regimen as fixed effects.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Difference in least square means</param_type>
            <param_value>1.807</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.488</ci_lower_limit>
            <ci_upper_limit>2.126</ci_upper_limit>
            <estimate_desc>Difference in least squares means and its 95% CI were from the ANOVA model including treatment and prior treatment regimen as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine BMD at Week 48</title>
        <description>Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented.</description>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in the Spine DXA Analysis Set (participants who received ≥ 1 dose of study drug and had nonmissing baseline spine BMD) with available data were analyzed.&#xD;
NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine BMD at Week 48</title>
          <description>Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented.</description>
          <population>Participants in the Spine DXA Analysis Set (participants who received ≥ 1 dose of study drug and had nonmissing baseline spine BMD) with available data were analyzed.&#xD;
NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="912"/>
                <count group_id="O2" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NDA Data Cut</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="742"/>
                    <count group_id="O2" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.861" spread="3.0889"/>
                    <measurement group_id="O2" value="-0.110" spread="3.7415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="881"/>
                    <count group_id="O2" value="436"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.557" spread="3.8441"/>
                    <measurement group_id="O2" value="-0.443" spread="4.1387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NDA Data Cut</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was from the analysis of variance (ANOVA) model including study treatment and prior treatment regimen as fixed effects.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Difference in least square means</param_type>
            <param_value>1.970</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.551</ci_lower_limit>
            <ci_upper_limit>2.390</ci_upper_limit>
            <estimate_desc>Difference in least squares means (LSM) and its 95% CI were from the ANOVA model including treatment and prior treatment regimen as fixed effects.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Participants</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was from the analysis of variance (ANOVA) model including study treatment and prior treatment regimen as fixed effects.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Difference in least square means</param_type>
            <param_value>2.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.549</ci_lower_limit>
            <ci_upper_limit>2.452</ci_upper_limit>
            <estimate_desc>Difference in least squares means (LSM) and its 95% CI were from the ANOVA model including treatment and prior treatment regimen as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Week 48</title>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in the Safety Analysis Set (randomized participants who received ≥ 1 dose of study drug) excluding participants with prior treatment of EFV/FTC/TDF.&#xD;
NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Week 48</title>
          <population>Participants in the Safety Analysis Set (randomized participants who received ≥ 1 dose of study drug) excluding participants with prior treatment of EFV/FTC/TDF.&#xD;
NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="708"/>
                <count group_id="O2" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NDA Data Cut</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.117"/>
                    <measurement group_id="O2" value="0.04" spread="0.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="696"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.115"/>
                    <measurement group_id="O2" value="0.03" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NDA Data Cut</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was from analysis of covariance (ANCOVA) model including study treatment and prior treatment as fixed effects and baseline serum creatinine as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>Difference in least squares means (LSM) and its 95% CI were from the analysis of covariance (ANCOVA) model including study treatment and prior treatment regimen as fixed effects and baseline serum creatinine as a covariate.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Participants</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was from analysis of covariance (ANCOVA) model including study treatment and prior treatment as fixed effects and baseline serum creatinine as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
            <estimate_desc>Difference in least squares means (LSM) and its 95% CI were from the analysis of covariance (ANCOVA) model including study treatment and prior treatment regimen as fixed effects and baseline serum creatinine as a covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48</title>
        <description>The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.&#xD;
EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.</description>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in EFV-Related Symptom Analysis Set with available data were analyzed.&#xD;
NDA Data Cut = participants through data cut for E/C/F/TAF NDA; All Participants = participants through Week 48 Data Cut</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48</title>
          <description>The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.&#xD;
EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.</description>
          <population>Participants in EFV-Related Symptom Analysis Set with available data were analyzed.&#xD;
NDA Data Cut = participants through data cut for E/C/F/TAF NDA; All Participants = participants through Week 48 Data Cut</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NDA Data Cut</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="3.06"/>
                    <measurement group_id="O2" value="-0.1" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="3.06"/>
                    <measurement group_id="O2" value="-0.1" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NDA Data Cut</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value comparing the 2 treatment groups was from the 2-sided Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Participants</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value comparing the 2 treatment groups was from the 2-sided Wilcoxon rank sum test.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96</title>
        <description>The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 96</time_frame>
        <population>Participants in the Full Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96</title>
          <description>The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Participants in the Full Analysis Set were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8"/>
                    <measurement group_id="O2" value="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: The E/C/F/TAF group was at least 12% worse than the Stay on Baseline Regimen group; alternative hypothesis: the E/C/F/TAF group was less than 12% worse than the in Stay on Baseline Regimen group.</non_inferiority_desc>
            <p_value>0.017</p_value>
            <p_value_desc>P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (STB, ATR, ATV/boosted+TVD).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in percentages</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
            <estimate_desc>The difference in percentages of virologic success and its 95% CI were calculated based on the MH proportion adjusted by the prior treatment regimen.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Week 48</title>
        <description>The percentage of participants achieving HIV-1 RNA &lt; 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants in the Full Analysis Set were analyzed. NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Week 48</title>
          <description>The percentage of participants achieving HIV-1 RNA &lt; 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Participants in the Full Analysis Set were analyzed. NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NDA Data Cut</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="799"/>
                    <count group_id="O2" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2"/>
                    <measurement group_id="O2" value="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="959"/>
                    <count group_id="O2" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5"/>
                    <measurement group_id="O2" value="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NDA Data Cut</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: The E/C/F/TAF group was at least 12% worse than the Stay on Baseline Regimen group; alternative hypothesis: the E/C/F/TAF group was less than 12% worse than the in Stay on Baseline Regimen group.</non_inferiority_desc>
            <p_value>0.29</p_value>
            <p_value_desc>P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (STB, ATR, ATV/boosted+TVD).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in percentages</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
            <estimate_desc>Difference in percentages of virologic success and its 95% CI were calculated based on the MH proportion adjusted by the prior treatment regimen.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Participants</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the E/C/F/TAF group was at least 12% worse than the Stay on Baseline Regimen group; alternative hypothesis: the E/C/F/TAF group was less than 12% worse than the in Stay on Baseline Regimen group.</non_inferiority_desc>
            <p_value>0.031</p_value>
            <p_value_desc>P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (STB, ATR, ATV/boosted+TVD).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in percentages</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
            <estimate_desc>Difference in percentages of virologic success and its 95% CI were calculated based on the MH proportion adjusted by the prior treatment regimen.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Week 96</title>
        <description>The percentage of participants achieving HIV-1 RNA &lt; 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 96</time_frame>
        <population>Participants in the Full Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Week 96</title>
          <description>The percentage of participants achieving HIV-1 RNA &lt; 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Participants in the Full Analysis Set were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6"/>
                    <measurement group_id="O2" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Null hypothesis: the E/C/F/TAF group was at least 12% worse than the Stay on Baseline Regimen group; alternative hypothesis: the E/C/F/TAF group was less than 12% worse than the in Stay on Baseline Regimen group.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <p_value_desc>P-value for the superiority test comparing the percentages of virologic success was from the CMH test stratified by the prior treatment regimen (STB, ATR, ATV/boosted+TVD).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in percentages</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
            <estimate_desc>Difference in percentages of virologic success and its 95% CI were calculated based on the MH proportion adjusted by the prior treatment regimen.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48</title>
        <description>The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.</description>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed. NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48</title>
          <description>The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.</description>
          <population>Participants in the Full Analysis Set with available data were analyzed. NDA Data Cut = participants through the data cut for the E/C/F/TAF NDA; All Participants = participants through the Week 48 Data Cut.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (NDA Data Cut)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="799"/>
                    <count group_id="O2" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="712" spread="267.9"/>
                    <measurement group_id="O2" value="690" spread="251.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (NDA Data Cut)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="773"/>
                    <count group_id="O2" value="374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="166.6"/>
                    <measurement group_id="O2" value="27" spread="160.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (All Participants)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="959"/>
                    <count group_id="O2" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="701" spread="261.8"/>
                    <measurement group_id="O2" value="689" spread="248.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (All Participants)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="937"/>
                    <count group_id="O2" value="449"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="164.6"/>
                    <measurement group_id="O2" value="24" spread="156.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NDA Data Cut: Change at Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>P-values were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Difference in least squares means</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14</ci_lower_limit>
            <ci_upper_limit>26</ci_upper_limit>
            <estimate_desc>Difference in least squares means (Diff in LSM), and its 95% CI were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. FTC/TDF+3rd Agent) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All Participants: Change at Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <p_value_desc>P-values were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Difference in least squares means</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8</ci_lower_limit>
            <ci_upper_limit>29</ci_upper_limit>
            <estimate_desc>Difference in least squares means and its 95% CI were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs.SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count at Weeks 96</title>
        <description>The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.</description>
        <time_frame>Baseline; Week 96</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>E/C/F/TAF</title>
            <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Treatment Regimen (SBR)</title>
            <description>Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen (E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF)) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count at Weeks 96</title>
          <description>The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.</description>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="959"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="959"/>
                    <count group_id="O2" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="701" spread="261.8"/>
                    <measurement group_id="O2" value="689" spread="248.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="892"/>
                    <count group_id="O2" value="427"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="181.6"/>
                    <measurement group_id="O2" value="42" spread="158.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <p_value_desc>P-values were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Difference in least squares means</param_type>
            <param_value>18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>38</ci_upper_limit>
            <estimate_desc>Difference in least squares means and its 95% CI were from the analysis of variance (ANOVA) model including treatment (E/C/F/TAF vs. SBR) and prior treatment regimen (STB, ATR, ATV/boosted+TVD) as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose date up to last dose date ( maximum: 307.7 weeks) plus 30 days</time_frame>
      <desc>Safety Analysis Set included participants who were randomized and received at least one dose of study drug.&#xD;
For All Cause Mortality: All Randomized Analysis Set included all participants who were randomized into the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Randomized Phase: E/C/F/TAF</title>
          <description>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; EVG/COBI/FTC/TAF; E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered once daily for up to 96 weeks in the Randomized Phase.</description>
        </group>
        <group group_id="E2">
          <title>Randomized Phase: Stay on Baseline Treatment Regimen (SBR)</title>
          <description>Participants stayed on their baseline emtricitabine(FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF (Stribild®); efavirenz (EFV)/FTC/TDF (Atripla®); ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks in the Randomized Phase.</description>
        </group>
        <group group_id="E3">
          <title>Extension Phase: E/C/F/TAF From E/C/F/TAF</title>
          <description>After completing 96 weeks of randomized treatment (E/C/F/TAF), all participants were given the opportunity to receive open-label E/C/F/TAF in the extension phase until it became commercially available, or until Gilead elected to terminate the development of E/C/F/TAF.</description>
        </group>
        <group group_id="E4">
          <title>Extension Phase: E/C/F/TAF From SBR</title>
          <description>After completing 96 weeks of randomized treatment (SBR), all participants were given the opportunity to receive open-label E/C/F/TAF in the extension phase until it became commercially available, or until Gilead elected to terminate the development of E/C/F/TAF.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Bacterial colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>H1n1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hepatitis syphilitic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Perineal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Reiter's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Maternal exposure during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Fanconi syndrome acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Substance use</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="620" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="286" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="298" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="144" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="959"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="477"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="905"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations affecting the analysis or results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

